Industry news and our latest thoughts on the issues that matter most in Cell Therapy.
hPSC-ATMP manufacture - Where are we now?
Featured news and insights
-
hPSC-ATMP manufacture - Where are we now?
Read our first white paper on Manufacturing in a series of white papers that we’ve produced post conducting our pilot study with Tillväxtverket.
Author, HOYA co-founder Heather Main.
-
An hPSC-ATMP innovation catalyst in Sweden - pilot study
Read the ATMP Sweden article summarising the hPSC-ATMP TVV pilot study and our company formation!
-
Gör Sverige ledande på framtidens läkemedel
Regeringen står nu inför ett vägval: växla upp arbetet med framtidens läkemedel eller ge bort möjligheten att utveckla dessa läkemedel till andra länder som också ligger i framkant.
-
Synergy in cell therapy development through mutual respect
The Novo Nordisk/Karolinska Institutet/St Erik/Vecura model, written and lived by Dr Heather Main, Co-founder at HOYA.
-
Regenerative Medicine: The Pipeline Momentum Builds
Clinical milestones, regulatory developments, and patient impact steadily advance for the cell and gene sector.
H1, 2022 report.
